Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Approves Corticosteroid Drug to Treat Duchenne Muscular Dystrophy

XTALKS VITALS NEWS

DMD

The drug has been approved to treat the rare genetic disorder in patients five years of age and older.

Share this!

February 13, 2017 | by Sarah Hand, M.Sc.

Just months after Sarepta Therapeutics’ Exondys 51 became the first US Food and Drug Administration (FDA) approved drug to treat Duchenne muscular dystrophy (DMD), the agency has approved Marathon Pharmaceuticals’ Emflaza (deflazacort). The drug has been approved to treat the rare genetic disorder in patients five years of age and older.

DMD is a disease characterized by progressive muscle weakness and deterioration, which primarily affects young boys. Emflaza is a corticosteroid designed to reduce inflammation and dampen the actions of the immune system. While corticosteroids are already in use for the treatment of DMD in other countries, the approval of Emflaza marks the first corticosteroid approval for this indication in the US.

“This is the first treatment approved for a wide range of patients with Duchenne muscular dystrophy,” said Dr. Billy Dunn, director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. “We hope that this treatment option will benefit many patients with DMD.”

A clinical trial involving 196 male patients between the ages of five and 15 years old was conducted to assess the effectiveness of deflazacort. All patients had a confirmed mutation in the dystrophin gene, the protein product of which is responsible for stabilizing muscle fibers.

After 12 weeks of being treated with deflazacort, the DMD patients saw improvements in muscle strength, compared to those taking the placebo. According to the FDA, patients on deflazacort also lost the ability to walk later compared to the placebo group, although this result was not statistically controlled for multiple comparisons.



“Today we celebrate FDA approval of Emflaza as a treatment option for kids and adults living with Duchenne muscular dystrophy,” said Steven M. Derks, President and CEO of the Muscular Dystrophy Association (MDA). “This approval follows decades of MDA research — including early-stage development and testing of Emflaza in DMD patients — that was made possible by the hard work, dedication and unwavering commitment of our donors and sponsors.

“Drugs like Emflaza aren't developed in silos, but rather through the combined efforts of biotechs and drug companies, patient organizations like MDA, corporate partners and donors, and the families who are there every step of the way to see it through. We are grateful to be part of such a welcome new development in the DMD landscape — and, more importantly, to belong to such a giving and dedicated community.”

In September of 2016, Exondys 51 became the first drug to be approved to treat DMD. Just three months later, the FDA approved Spinraza for the treatment of spinal muscular atrophy, another rare neuromuscular disease.


Keywords: FDA, Duchenne Muscular Dystrophy, Corticosteroids


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
German Merck Launches Spinoff Immuno-Oncology Company

June 22, 2017 - Merck KGaA has announced the launch of iOnctura SA, a new immuno-oncology company built around two assets from the Healthcare R&D portfolio of the pharmaceutical company.

Featured In: Biotech News


Ikea Promotes Food Products by Offering Fill-in-the-Blanks Recipe Sheets

June 21, 2017 - In an effort to promote the company’s food business, Ikea recently launched a set of recipes printed on parchment paper that encourage consumers to “fill-in-the-blanks” with ingredients, fold the paper and cook the bag in the oven.

Featured In: Food News


Nanomaterial Promotes Bone Growth after Spinal Fusion Surgery

June 21, 2017 - Researchers at Northwestern University have developed a bioactive nanomaterial capable of effectively stimulating bone regeneration after spinal fusion surgery.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Drug Development During the Last Week

REGISTER FOR THESE WEBINARS

Serialized? Yes. But are Products Still Being Diverted?


Quantitative Protein Profiling in FFPE to Characterize Toxicities Associated with Immune Checkpoint Inhibitors


Are You Choosing the Right Model? A Guide to Selecting Your Next Immuno-Oncology Model


Imaging-based Subtypes of Pancreatic Cancer


Copyright © 2016-2017 Honeycomb Worldwide Inc.